WO2012120532A2 - Peptides cycliques à chaîne courte - Google Patents
Peptides cycliques à chaîne courte Download PDFInfo
- Publication number
- WO2012120532A2 WO2012120532A2 PCT/IN2012/000078 IN2012000078W WO2012120532A2 WO 2012120532 A2 WO2012120532 A2 WO 2012120532A2 IN 2012000078 W IN2012000078 W IN 2012000078W WO 2012120532 A2 WO2012120532 A2 WO 2012120532A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aib
- phe
- ame
- har
- nle
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 152
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 108
- 125000004122 cyclic group Chemical group 0.000 title claims abstract description 61
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 170
- 235000001014 amino acid Nutrition 0.000 claims description 82
- 229940024606 amino acid Drugs 0.000 claims description 81
- 150000001413 amino acids Chemical class 0.000 claims description 78
- 208000001132 Osteoporosis Diseases 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 32
- 210000000988 bone and bone Anatomy 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- FUOOLUPWFVMBKG-UHFFFAOYSA-N alpha-amino-isobutyric acid Natural products CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 16
- -1 His (H) Chemical compound 0.000 claims description 15
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 15
- GPYTYOMSQHBYTK-LURJTMIESA-N (2s)-2-azaniumyl-2,3-dimethylbutanoate Chemical compound CC(C)[C@](C)([NH3+])C([O-])=O GPYTYOMSQHBYTK-LURJTMIESA-N 0.000 claims description 14
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 13
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 claims description 12
- MXECDVKIKUSSNC-JTQLQIEISA-N (2s)-2-amino-3-(2-fluorophenyl)-2-methylpropanoic acid Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1F MXECDVKIKUSSNC-JTQLQIEISA-N 0.000 claims description 10
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- LWHHAVWYGIBIEU-LURJTMIESA-N (2s)-2-methylpyrrolidin-1-ium-2-carboxylate Chemical compound [O-]C(=O)[C@]1(C)CCC[NH2+]1 LWHHAVWYGIBIEU-LURJTMIESA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 8
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 8
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 claims description 7
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 239000000262 estrogen Substances 0.000 claims description 7
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims description 6
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 235000013477 citrulline Nutrition 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- 206010065687 Bone loss Diseases 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 229930182827 D-tryptophan Natural products 0.000 claims description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 4
- 229930195709 D-tyrosine Natural products 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002124 endocrine Effects 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 4
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- ZTTWHZHBPDYSQB-LBPRGKRZSA-N (2s)-2-amino-3-(1h-indol-3-yl)-2-methylpropanoic acid Chemical compound C1=CC=C2C(C[C@@](N)(C)C(O)=O)=CNC2=C1 ZTTWHZHBPDYSQB-LBPRGKRZSA-N 0.000 claims description 3
- MVAJOGCZNRWTRF-UHFFFAOYSA-N 2-amino-2-methyl-5-phenylpentanoic acid Chemical compound OC(=O)C(N)(C)CCCC1=CC=CC=C1 MVAJOGCZNRWTRF-UHFFFAOYSA-N 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- 235000008729 phenylalanine Nutrition 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- XOQZTHUXZWQXOK-UHFFFAOYSA-N 2-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)C(N)CCCC1=CC=CC=C1 XOQZTHUXZWQXOK-UHFFFAOYSA-N 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000000580 secretagogue effect Effects 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 101001006370 Actinobacillus suis Hemolysin Proteins 0.000 claims 17
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract description 37
- 108010069514 Cyclic Peptides Proteins 0.000 abstract description 37
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 67
- 102000003982 Parathyroid hormone Human genes 0.000 description 58
- 239000000199 parathyroid hormone Substances 0.000 description 58
- 239000011347 resin Substances 0.000 description 53
- 229920005989 resin Polymers 0.000 description 53
- 229960001319 parathyroid hormone Drugs 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 238000010511 deprotection reaction Methods 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 17
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 15
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000001270 agonistic effect Effects 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000010647 peptide synthesis reaction Methods 0.000 description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 210000001853 liver microsome Anatomy 0.000 description 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 7
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 101710191547 Peptidyl-tRNA hydrolase 1 Proteins 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 0 CCc1cc(OC)ccc1-c1ccc(CC(C)(*)C(O)=O)cc1 Chemical compound CCc1cc(OC)ccc1-c1ccc(CC(C)(*)C(O)=O)cc1 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000037147 Hypercalcaemia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000001195 anabolic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000000148 hypercalcaemia Effects 0.000 description 4
- 208000030915 hypercalcemia disease Diseases 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010049088 Osteopenia Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003262 anti-osteoporosis Effects 0.000 description 3
- 230000037118 bone strength Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 2
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940062527 alendronate Drugs 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- JOOIZTMAHNLNHE-NRFANRHFSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JOOIZTMAHNLNHE-NRFANRHFSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- IECZEINPZOFWNU-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonylamino)cyclopentane-1-carboxylic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC1(C(=O)O)CCCC1 IECZEINPZOFWNU-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- HOZZVEPRYYCBTO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(C)(C)C(O)=O)C3=CC=CC=C3C2=C1 HOZZVEPRYYCBTO-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- HYOWVAAEQCNGLE-UHFFFAOYSA-N CC(Cc1ccccc1)(C(O)=O)N Chemical compound CC(Cc1ccccc1)(C(O)=O)N HYOWVAAEQCNGLE-UHFFFAOYSA-N 0.000 description 1
- WLVXKTIBRNXBIF-UHFFFAOYSA-N CCc1cc(OC)ccc1-c1ccc(CC(C(O)=O)N)cc1 Chemical compound CCc1cc(OC)ccc1-c1ccc(CC(C(O)=O)N)cc1 WLVXKTIBRNXBIF-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000001730 Familial dysautonomia Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027294 Menkes' syndrome Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 101710149426 Parathyroid hormone 2 receptor Proteins 0.000 description 1
- 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 description 1
- 229940116372 Parathyroid hormone receptor agonist Drugs 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101100031555 Rattus norvegicus Pth1r gene Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 201000001638 Riley-Day syndrome Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 108700000288 parathyroid hormone (1-28) Proteins 0.000 description 1
- 108010073509 parathyroid hormone (1-31) Proteins 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960000338 teriparatide acetate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- FJGIHZCEZAZPSP-UHFFFAOYSA-N tetrahedrane Chemical compound C12C3C1C32 FJGIHZCEZAZPSP-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel cyclic short chain peptides of general formula (I) having beneficial pharmacological properties, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
- the present invention also relates to processes for preparing compounds of general formula (I), their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
- Osteoporosis is a skeletal disorder characterised by diminished bone mass, decreased bone mineral density (BMD), decreased bone strength and associated with an increased risk of bone fracture (Lane J. M., et al., Clin. Orthop. Relat. Res., 372, 2000, 139-150). Osteoporotic fractures most often occur in the vertebrae, hips or the femoral neck. These fractures severely impair the quality of life because of pain, long-lasting immobility and poor recovery. Bone comprises of several different cell types. Osteoblast (bone formation) lays down new bone from the mineral present in the extracellular milieu around the cells. Osteoclasts (bone loss) remove old bones, releasing the minerals compiled within bone back into the extracellular matrix.
- BMD bone mineral density
- Osteoporosis occurs when the rate of the bone resorption is greater than the rate of bone formation (Seeman E., et al., N. Engl. J. Med., 354(21), 2006, 2250-2261).
- Postmenopausal estrogen deficiency is the most common cause of osteoporosis in women, as estrogen puts a break on osteoclast lifespan.
- Other major risk factors in the development of osteoporosis include: low calcium intake, vitamin D deficiency, type-1 diabetes, rheumatoid arthritis, long-term use of medication such as anticonvulsants and corticosteroids and low levels of testosterone in men (Cole Z.
- PTH Native human Parathyroid Hormone
- PTH in-turn, maintains the serum calcium level by directly or indirectly promoting calcium entry into the blood.
- PTH contributes to net gastrointestinal absorption of calcium by favouring the renal synthesis of the active form of vitamin D.
- PTH promotes calcium reabsorption from bone, indirectly by stimulating differentiation of the osteoclasts (bone-resorbing cells).
- Administration of PTH via parenteral route efficiently increases bone mineral density (BMD), bone strength and reduces the incidence of new osteoporotic fractures in osteoporotic patients (Greenspan S. L., et al., Ann. Intern. Med., 146(5), 2007, 326- 339; Neer R. M., et al., N. Engl. J. Med., 344, 2001, 1434-1441).
- PTH receptor which is expressed in numerous tissues, most abundantly in kidney, bone and growth plate chondrocytes (Lanske B., et al., Crit. Rev. Eukaryot. Gene Expr., 8, 1998, 297-320).
- the PTH receptor is homologous in primary structure to a number of other receptors that bind peptide hormones, such as secretin, calcitonin and glucagon; together, these receptors form a distinct family called G-protein coupled receptors (GPCR/ GPCRs) family B (Kolakowski L. F., Receptor Channels, 2, 1994, 1-7).
- the GPCR comprise an extracellular N-terminal domain of 100-160 residues, connected to a juxtamembrane domain (J-domain) of seven membrane-spanning a-helices with intervening loops and a C-terminal tail (Donnelly D., FEBS Letts., 409, 1997, 431- 436).
- the Class B GPCRs are activated by endogenous peptide ligands of intermediate size, typically 30-40 amino acids (Hoare, S. R. J., Drug Discovery Today, 10, 2005, 423-427). A general mechanism of peptide ligand interaction with class B GPCRs has emerged and is termed as the 'two-domain' model.
- the C-terminal portion of the peptide binds the N-domain of the receptor, confirm binding of ligand with the receptor and the N-terminal ligand region binds the J-domain, an interaction that activates the receptor and stimulates intracellular signalling (Ji T. H., et al., J. Biol. Chem., 273, 1988, 17299-17302; Hjorth, S. A., et al., Regulatory Peptides, 64, 1996, 70).
- PTH binds to the PTH receptor with affinity in the nM range; the ligand- occupied receptor transmits a signal across the cell membrane to intracellular effector enzymes through a mechanism that involves intermediary heterotrimeric GTP-binding proteins (G proteins).
- G proteins GTP-binding proteins
- the primary intracellular effector enzyme activated by the PTH receptor in response to PTH peptide is adenylyl cyclase (AC) (Goltzman D., J. Bone Miner. Res., 15(3), 2000, 605-608).
- PTH induces increase in the second messenger, cyclic adenosine monophosphate (cAMP) which regulates the poorly characterized downstream cellular processes involved in bone remolding (Juppner H., et al., Science, 254, 1991, 1024-1026).
- cAMP cyclic adenosine monophosphate
- Other signalling pathways of this receptor such as elevation of intracellular calcium, phospholipase C-dependent and independent activation of protein kinase C, have been described.
- the parathyroid hormone and its derivatives represent potential therapeutic agent for the treatment of osteoporosis (Slovik D. M., et al., J. Bone Miner. Res., 1, 1986, 377-381 ; Dempster D. W., et al., Endocr. Rev., 14, 1993, 690-709).
- Synthetic PTH (1 -34) exhibits full bioactivity in most cell-based assay systems, has potent anabolic effects on bone mass in animals and has recently been shown to reduce the risk of bone fracture in postmenopausal osteoporotic women.
- daily subcutaneous injections of low doses of PTH (1-34) were shown to result in impressive bone formation in the spine and femoral neck with significant reduction in incidence of vertebral fractures (Neer R. M., et al., N. Engl. J. Med., 344, 2001, 1434-1441; Dempster D. W., et al., Endocr. Rev., 14, 1993, 690-709).
- PTH as one of the most efficacious agents tested for osteoporosis.
- PTH (1-34) in the form of teriparatide acetate has been approved for the treatment of osteoporosis.
- PTH derivatives include polypeptides that have amino acid substitutions or are truncated relative to the full-length molecule. Both the N and C-terminal truncated forms of PTH (1-34) has been studied. Additionally, amino acid substitutions within the truncated polypeptides have also been investigated. (Azurani A., et al., J. Biol. Chem., 271, 1996, 14931-14936).
- Truncated PTH (1-34) derivatives such as cyclised PTH (1-17), PTH (1-28), PTH (1 -31) and PTH (1 -1 1 ) are active in most assay systems and promote bone-formation (Whitfield J. F., et al., J. Bone Miner. Res., 12, 1997, 1246-1252; WO 2007 / 1301 13 A2; WO 2008 / 068487; Whitefild J. F., et al., Calcif. Tissue Int., 56, 1995, 227-231 ; Rixon R. H., et al., J. Bone Miner.
- PTH is highly susceptible to protease attack and must be stored at low temperature due to its low stability.
- tolerability is limited by transient mobilization of calcium and hypercalcemia also the toxicological data and in particular the unfavourable results of cancerogenesis studies (dose and treatment duration dependent increased risk of osteosarcoma) induce a cautious use of PTH (1 - 34) (Vahle J. L., Toxicol. Pathos., 32(4), 2004, 426-438; Whitfiel J.
- PTH(l-l l) analogs [Ala 3 , Glnio, Argn]-PTH(1-1 1), [Ala 3 , Glnio, Har, ,]-PTH(l -l l) and [Aib 1 >3 ; Gln, 0 ; Harness]-PTH(1-1 1)
- PTH (1-14) analogs such as [AC5C1, Aib 3 , Glnio, Harn, Ala )2 , Trpi ]PTH(l-14) stimulate cAMP, in nM range (WO 03/009804; WO 04/093902).
- short chain peptide analogues consisting of 1 1 amino acids (derivatives of first 1-1 1 residues of PTH peptide, Seq. ID. No.2) can activate the PTH receptor (in vitro) with low potency (WO 04/067021 ), however, in animal models (in vivo) bone-anabolic activity of these analogues has not been reported.
- agonistic activity on cAMP- signalling pathway of the PTH receptor (in vitro) alone is not at all predictive for bone- anabolic activity in vivo.
- PTH (1-15) 'SVSEIQLMHNLGKHL 15 (Seq. ID No: 3)
- PTH parathyroid hormone peptide
- Xaal and Xaa3 represent either Aib or AC 5 C
- Xaa8 represent Nle
- XaalO represent S & E
- Xaal l represent Har
- Xaal 2 represent Ala
- Xaal4 represent W (WO 03 / 009804 A2; US 2006 / 7153951 B2; US 2007 / 01 17157 Al ; US 2007 / 0203071 Al ; US 2006 / 0019902 Al ; US 2007 / 0 . 161569 Al ; US 2007 / 011 1946 Al ; Gardella T. J., et al., J. Biol. Chem. 2000, 275, 21836-21843; Gardella T.
- the present invention describes a group of novel cyclic short chain peptides that function as agonist of the PTH receptor, having different degree of affinity towards the PTH / PTH-1 receptor and useful for the treatment of osteoporosis.
- These cyclic peptides are defined by the general formula (I) as given below.
- the cyclic peptides of the present invention are useful for the treatment or prevention of hypoparathyroidism and diseases characterized by bone mass reduction or bone loss, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair.
- the present invention provides novel cyclic peptides of formula (I), which primarily act as a PTH/ PTH-1 receptor agonist. These cyclic peptides exhibit increased metabolic stability against proteolytic enzymes. Most of these cyclic peptides were found to be stable in rat plasma upto 24 hours (in vitro), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, most of these cyclic peptides can also be delivered by oral route of administration.
- a preferred embodiment of the present invention is to provide novel cyclic peptides of general formula (I), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them or their mixtures, suitable for the treatment/mitigation/regulation of bone disorders.
- compositions containing cyclic peptides of general formula (I), their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other components normally employed in their manufacture are provided.
- novel cyclic peptides of the present invention as agents for stimulating new bone formation and treating and / or preventing osteoporosis and related bone disorders, by administering a therapeutically effective and non-toxic amount of the cyclic peptides of formula (I), or their pharmaceutically acceptable compositions to the mammals those are in need of such treatment.
- Aib a-Amino-isobutyric acid
- aMe-APPA 2-amino-2-methyl-5-phenylpentanoic acid
- ccMe-Bip(OMe) alpha-methylated Bip(OMe)
- aMe-Pro alpha-methyl-Proline
- aMe-Phe alpha-methyl-phenylalanine
- aMe-2F-Phe alpha-methyl-2-fluorophenylalanine
- a e-2,6-F-Phe alpha-methyl-2,6-diflurophenylalanine
- ccMe-Trp alpha-methyl-Tryptophan
- aMe-Tyr alpha-methyl-Tyrosine
- ACN Acetonitrile
- cAMP Adenosine 3',5'-cyclic monophosphate
- DIPCDI Di-isopropylcarbodiimide
- DIPEA Diisopropylethylamine
- Fmoc Fluorenylmethoxycarbonyl
- HoSer Homoserine
- HOBt 1-Hydroxybenzotriazole
- HOAt 7-Aza-hydroxybenzotriazole
- HBTU 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyl aminium hexafluorophosphate
- HPLC High Performance Liquid Chromatography
- PTH Parathyroid Hormone
- PTH-lr agonist Parathyroid Hormone receptor agonist
- PyBOP Benzotriazole-l -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
- Pyr Pyroglutamic acid
- TIPS Triisopropylsilane
- TFA Trifluoroacetic acid
- Figure 1 Examples of orthogonally protected amino acids used in Fmoc based-solid phase peptide synthesis (SPPS) of short-chain peptides.
- SPPS Fmoc based-solid phase peptide synthesis
- Figure 2 In vitro DRC and EC 50 determination of PTH(l-34) ( Figure A) and Seq. ID No. 133 ( Figure B), in Rat PTH-1 R assay (agonistic activity, measured by amount of cAMP released).
- Figure 3 In vivo DRC study with Seq. ID No. 168 (Figure A: % increase in serum Ca 2+ levels; Figure B: % decrease in serum P0 4 levels), in OVX Female Rat.
- Figure 4 Changes in biochemical parameters and femur weight, in OVX Rat after 6 weeks treatment with Seq. ID No. 247 and PTH(l-34).
- synthetic cyclic short chain peptides having the structural formula (I), which showed PTH-1 receptor agonistic activity are disclosed. These cyclic short chain peptides exhibit increased metabolic stability to proteolytic cleavage, as most of cyclic peptides were found to be stable in rat plasma upto 24 hours (in vitro), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro).
- cyclic peptides can also be delivered by oral routes of administration, for the treatment / prevention of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair.
- the present invention thus discloses novel cyclic short chain peptides as PTH receptor agonist having the following structure (I).
- ⁇ ' represents the groups -NH-Ri or R3-CO-NH- , wherein Ri represents hydrogen or optionally substituted linear (Cns) alkyl chain, or suitable amino acids preferably selected from pyroglutamic acid (Pyr), Pro (P), alpha-methyl-Proline (aMe-P), Val (V), alpha-methyl-Valine (aMe-V); R 3 is selected from optionally substituted linear (Ci-] 8 ) alkyl chain, (Cr 6 )alkoxy, (C 3 -C 6 ) cycloalkyl, aryl, heteroaryl or arylalkyl groups;
- the aryl group is selected from phenyl, napthyl, indanyl or biphenyl, groups; the heteroaryl group is selected from pyridyl, thienyl, furyl, imidazolyl, benzofuranyl groups; the arylalkyl groups represent groups wherein the aryl group is attached to an alkyl groups as defined elsewhere in the specification.
- 'B' represents -COOR 2 , -CONHR 2 or CH 2 OR 2, wherein R 2 represents H or suitable amino acids.
- Preferred amino acids may be selected from the group comprising of Val (V), alpha-methyl-Valine (aMe-V), and the like;
- Each of Zi ; Z 3 & Z 2 may be same or different and independently represents a naturally or unnaturally occurring amino acids selected from the group comprising of Ser (S), Val (V), Pro (P), alpha-methyl-Proline (aMe-P), Gly (G), Ala (A), a-amino- isobutyric acid (Aib), 1 -amino cyclopropane carboxylic acid (AC 3 C), 1-amino- cyclopentanecarboxylic acid (AC 5 C), 1-amino-cyclohexanecarboxylic acid (AC 6 C); preferably, each of Zi, Z 3 & Z ) represents amino acid selected from Ala (A), a-amino- isobutyric acid (Aib), 1-amino cyclopropane carboxylic acid (AC 3 C) or 1-amino- cyclopentanecarboxylic acid (AC5C);
- Z 2 represents either a Val (V) or alpha-methyl-valine (aMe-V);
- Z4 represents a naturally or unnaturally occurring amino acids selected from the group comprising of Glu(E), Asp(D).
- Each of Z 6 & Z10 may be same or different and independently represents a naturally or unnaturally occurring amino acid selected from the group comprising of Ser (S), Homoserine (HoSer), Lys (K), Orn (Ornithine), Glu (E), Homoglutamic acid (HoGlu), Asp (D); wherein, the side chains of Z 6 and Z10 having acidic or basic group such as Lys (K), Glu (E) or Asp (D) lead to the formation of lactam bridge or the side chain of Z 6 and Z ]0 having alcohol group such as Ser (S) or Homoserine (HoSer) are cross-linked as a diester bridge, with dicarboxylic acids, such as succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid or sebacic acid; preferably each of Z 6 & Z10 represents amino acid selected from Ser (S), Lys (K), Glu (E) or Asp (D);
- Z 8 represents a naturally or unnaturally occurring amino acid selected from the group comprising of Met, alpha-methyl-Valine (ocMe-V), Leu, Nle, HoLeu, Val; preferably Z 8 represents amino acid selected from Met, Leu or Val;
- ] 1 & Zi 3 may be same or different and independently represents a naturally or unnaturally occurring amino acid selected from the group comprising of Lysine (K), Arginine (R), Homoarginine (Har), Ornithine (Orn), Citrulline (Cit), Phenyl alanine (F), alpha-methyl-phenylalanine (aMe-Phe-), alpha-methyl-2-fluorophenylalanine (ocMe-2F-Phe-) or alpha-methyl-2,6-difIurophenylalanine (o Me-2,6-F-Phe-) or 2- fluorophenylalanine (2F-Phe-); preferably, each of Zn & Zj 3 represents amino acid selected from Lysine (K), Arginine (R), Homoarginine (Har) or Citrulline (Cit);
- Zn may be present or absent.
- Zj 4 when present represents a naturally or unnaturally occurring amino acid selected from the group comprising of 2'-ethyl-4'- meihoxy-biphenylalanine (Bip(OMe)), ot-methylated Bip(OMe) [aMe-Bip(OMe)], alpha-methyl-tryptophan (ocMe-Trp), alpha-methyl-tyrosine (aMe-Tyr), Tryptophan (W), Tyrosine (Y), D-Tryptophan ( ⁇ /W), D-Tyrosine (dY), alpha-methyl-phenylalanine (aMe-Phe-), alpha-methyl-2-fluorophenylalanine (aMe-2F-Phe-), alpha-methyl-2,6- diflurophenylalanine (aMe-2,6-F-Phe-) or 2-fluorophenylalanine (2F-Phe-); preferably
- Zi5 may be present or absent.
- Zj 5 when present represents a naturally or unnaturally occurring amino acid selected from the group comprising of 2-aminb-5- phenylpentanoic acid (APPA) or 2-amino-2-methyl-5-phenylpentanoic acid (aMe- APPA);
- APPA 2-aminb-5- phenylpentanoic acid
- aMe- APPA 2-amino-2-methyl-5-phenylpentanoic acid
- 'unnatural amino acids' or 'non-natural amino acids' preferably represents either replacement of L-amino acids with corresponding D-amino acids such as replacement of L-Ala with D-Ala and the like or suitable modifications of the L or D amino acids, amino alkyl acids, either by
- - a-alkylation such as substitution of Ala with cc-methyl Ala (Aib), replacement of Met with -methyl Met;
- - substitution on the side chain of amino acid such as substitution of aromatic amino acid side chain with halogen, (C1-C3) alkyl, aryl groups, more specifically the replacement of Phe with halo Phe;
- alkyl used herein, either alone or in combination with other radicals, denotes a linear or branched radical containing one to eighteen carbons, such as methyl, ethyl, H-propyl, w-butyl, amyl, «-pentyl, w-hexyl, heptyl, octyl, decyl, tetradecyl, octadecyl and the like.
- cycloalkyl used herein, either alone or in combination with other radicals, denotes a radical containing three to seven carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- 'amino acid' as employed herein alone or as part of another group includes, without limitation, an amino group and a carboxyl group linked to the same carbon, referred to as 'a' carbon.
- the absolute 'S' configuration at the 'a' carbon is commonly referred to as the 'L' or natural configuration.
- the 'R' configuration at the 'a' carbon is commonly referred to as the 'D' amino acid.
- both the 'a-substituents' is equal, such as hydrogen or methyl, the amino acids are Gly or Aib and are not chiral.
- the compounds of the invention include peptide amides and non-amides and peptide analogues, including but not limited to the following:
- 'PTH receptor modulator or agonist' refers to a compound that acts at the PTH-1 and/or PTH-2 receptor to alter its ability to regulate downstream signaling events, such as cAMP production.
- Example of receptor modulators includes agonist, partial agonist, inverse agonist and allosteric potentiators.
- the synthetic isolated cyclic peptides described herein primarily acts as PTH receptor agonists.
- These synthetic cyclic peptides exhibit desirable in vitro PTH receptor agonist activity in UMR-106 cells, in the range of 1-1000 nM concentration. PTH receptor agonistic activity is assessed by estimation of amount of cAMP released by the test compounds.
- Some of the cyclic peptides prepared showed increase in BMD and / or bone strength, when tested in vivo, in OVX rat model, thus making them ideal therapeutic candidates for the treatment and prevention of osteoporosis.
- These new classes of cyclic peptides can be administered by oral or other non-invasive routes or parenteral routes of administration.
- the present invention provides cyclic short chain peptides of formula (I) pharmaceutical compositions employing such cyclic short chain peptides either alone or in combination and for methods of using such cyclic peptides.
- the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of cyclic peptides of formula (I), alone or in combination(s), with a pharmaceutically acceptable carrier.
- a method for treating or delaying the progression or onset of osteoporosis especially primary osteoporosis, endocrine osteoporosis, postmenopausal osteoporosis, hereditary and congentinal forms of osteoporosis, wherein, therapeutically effective amount of cyclic peptides of formula (I) or their combination(s) can be administered to a mammal, example, human and a patient in need of treatment.
- cyclic short chain peptides of the present invention can be synthesized using the methods described below, together with conventional techniques known to those skilled in the art of peptide synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but not limited to those described below.
- the cyclic short chain peptides thereof described herein may be produced by chemical synthesis using suitable variations of both the solution-phase (preferably, using Boc- chemistry; as generally described in M. Bodansky, A. Bodansky, "The practice of peptide synthesis", Springer-Verlag, Berlim, 1984; E. Gross, J. Meinhofer, "The peptide synthesis, analysis, biology", Vol. 1, Academic Press, London, 1979) and or solid-phase techniques, such as those described generally in G. Barany & R. B. Merrifield, "The peptides: Analysis, synthesis, Biology”; Volume 2- "Special methods in peptide synthesis, Part A", pp. 3-284, E. Gross & J. Meienhofer, Eds., Academic Press, New York, 1980; and in J. M. Stewart and J. D. Young, "Solid-phase peptide synthesis” 2nd Ed., Pierce chemical Co., Rockford, II, 1984.
- the preferred strategy for preparing the cyclic peptides of this invention is based on the use of Fmoc-based SPPS approach, wherein Fmoc (9- fluorenylmethoxycarbonyl) group is used for temporary protection of the a-amino group, in combination with the acid labile protecting groups, such as tert- butoxycarbonyl (Boc), tert-butyl (Bu l ), Trityl (Trt) groups ( Figure 1), for temporary protection of the amino acid side chains, if present (see for example E. Atherton & R.C.
- the cyclic short chain peptides can be synthesized in a stepwise manner on an insoluble polymer support (resin), starting from the C-terminus of the peptide.
- the synthesis is initiated by appending the C-terminal amino acid of the peptide to the resin through formation of an amide, ester or ether linkage. This allows the eventual release of the resulting peptide as a C-terminal amide, carboxylic acid or alcohol, respectively.
- the C-terminal amino acid and all other amino acids used in the synthesis are required to have their a-amino groups and side chain functionalities (if present) differentially protected (orthogonal protection), such that the a-amino protecting group may be selectively removed during the synthesis, using suitable base such as 20% piperidine solution, without any premature cleavage of peptide from resin or deprotection of side chain protecting groups, usually protected with the acid labile protecting groups.
- the coupling of an amino acid is performed by activation of its carboxyl group as an active ester and reaction thereof with unblocked a-amino group of the N-terminal amino acid appended to the resin. After every coupling and deprotection, peptidyl-resin was washed with the excess of solvents, such as DMF, DCM and diethyl ether. The sequence of a-amino group deprotection and coupling is repeated until the desired peptide sequence is assembled (Scheme 1). The peptide is then cleaved from the resin with concomitant deprotection of the side chain functionalities, using an appropriate cleavage mixture, usually in the presence of appropriate scavengers to limit side reactions. The resulting peptide is finally purified by reverse phase HPLC.
- the synthesis of the peptidyl-resins required as precursors to the final peptides utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA).
- Preferred for use in this invention is Fmoc-PAL-PEG-PS resin, 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-j?-methyl benzhydrylamine resin (Fmoc-Rink amide MBHA resin), 2-chloro-Trityl-chloride resin or p- benzyloxybenzyl alcohol resin (HMP resin) to which the C-terminal amino acid may or may not be already attached.
- Fmoc-PAL-PEG-PS resin 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-j?-methyl benzhydrylamine resin
- the C-terminal amino acid is not attached, its attachment may be achieved by HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
- HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
- 2-Chloro-trityl resin coupling of first Fmoc-protected amino acid was achieved, using DIPEA.
- N- terminal protection of peptidyl resin was selectively deprotected using 10-20 % piperidine solution. After every coupling and deprotection, excess of amino acids and coupling reagents were removed by washing with DMF, DCM and ether.
- Coupling of the subsequent amino acids can be accomplished using HOBt or HOAt active esters produced from DIPCDI/ HOBt or DIPCDI/HOAt, respectively.
- HOBt or HOAt active esters produced from DIPCDI/ HOBt or DIPCDI/HOAt, respectively.
- complete coupling can be achieved using a combination of highly efficient coupling agents such as HBTU, PyBOP or TBTU, with additives such as DIPEA.
- the synthesis of the cyclic peptides described herein can be carried out by using batchwise or continuous flow peptide synthesis apparatus, such as CS-Bio or AAPPTEC peptide synthesizer, utilizing the Fmoc/trityl protection strategy.
- the non- natural non-commercial amino acids present at different position were incorporated into the peptide chain, using one or more methods known in the art.
- Fmoc- protected non-natural amino acid was prepared in solution, using appropriate literature procedures.
- Fmoc-protected APPA analogs were prepared from L-pyroglutamic acid, in good enantiomeric purity, using modified literature procedure (Betsbrugge J.V., et al., Tetrahedron, 54, 1988, 1753- 1762).
- the Fmoc-protected cc-methylated amino acids were prepared using asymmetric Strecker synthesis (Boesten, W.H.J., et al., Org. Lett., 3(8), 2001, 1 121 -1 124; Cativiela C, Diaz-de-villegas M. D., Tetrahedran Asymmetry, 9, 1988, 3517-3599).
- the resulting derivative was then used in the step-wise synthesis of the peptide.
- the required non-natural amino acid was built on the resin directly using synthetic organic chemistry procedures and a linear peptide chain were building.
- Figure 1 Examples of some of the protected amino acids used in Fmoc based-solid phase peptide synthesis (SPPS) of short-chain peptides.
- SPPS Fmoc based-solid phase peptide synthesis
- the peptide-resin precursors for their respective cyclic peptides may be cleaved and deprotected using suitable variations of any of the standard cleavage procedures described in the literature (King D.S., et al., Int. J. Peptide Protein Res., 1990, 36, 255- 266).
- a preferred method for use in this invention is the use of TFA cleavage mixture, in the presence of water and TIPS as scavengers.
- the peptidyl-resin was incubated in TFA / Water /TIPS (95:2.5:2.5) for 1.5 - 4 hrs at room temperature.
- the cleaved resin is then filtered off and the TFA solution is concentrated or dried under reduced pressure.
- the resulting crude peptide is either precipitated or washed with Et 2 0 or is re-dissolved directly into DMF or 50 % aqueous acetic acid for purification by preparative HPLC.
- the cyclic short chain peptides with the desired purity can be obtained by purification using preparative HPLC.
- the solution of crude peptide is injected into a semi-Prep column (Luna 10 ⁇ ; C] 8 ; 100 A ), dimension 250 X 50 mm and eiuted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 40 mL /min with effluent monitoring by PDA detector at 220 nm.
- the structures of the purified cyclic peptides can be confirmed by Electrospray Mass Spectroscopy (ES-MS) analysis.
- ES-MS Electrospray Mass Spectroscopy
- peptide prepared were isolated as trifluoro-acetate salt, with TFA as a counter ion, after the Prep-HPLC purification.
- some peptides were subjected for desalting, by passing through a suitable ion exchange resin bed, preferably through anion-exchange resin Dowex SBR P(C1) or an equivalent basic anion-exchange resin.
- TFA counter ions were replaced with acetate ions, by passing through suitable ion-exchange resin, eiuted with dilute acetic acid buffer.
- selected peptides, with the acetate salt was treated with 4 M HC1.
- the Fmoc-protection on first amino acid, coupled with resin was deprotected, using a 10-20% piperidine solution, followed by the coupling the Fmoc-protected second amino acid, using a suitable coupling agents, and as described above.
- the repeated cycles of deprotection, washing, coupling and washing were performed until the desired peptide chain was assembled on resin, as per general Scheme 1 above.
- Aib-V-Aib-EI -(aMe-2F-Phe)-Nle-HE-Har-A-Cit-( Me-2F-Phe) was assembled on an automated CS-Bio 536 PepSynthesiserTM using Fmoc solid phase peptide synthesis (SPPS) approach (Scheme 2).
- SPPS Fmoc solid phase peptide synthesis
- the Fmoc amino acids and the 2-(lH-Benzotriazol-l- yl)-l,l,3,3-tetramethyluroniumtetrafluoroborate (TBTU) were packed together in vials and positioned in the amino acid module of the synthesizer.
- a stock solution of diisopropylethylamine (DIPEA; 0.9 M) and DMF were stored in reagent bottles, under dry nitrogen atmosphere.
- the resin, Fmoc-PAL-PEG- PS (0.38 mmol/g; lg) was dried over P 2 0 5j in vacuo (I hr) and swollen in freshly distilled DMF (5 mL).
- the swollen resin was slurry packed into a glass column and positioned in the synthesizer. All the synthetic cycles were carried out at a flow rate of 5 mL min "1 , Table 1.
- the resin was washed with freshly distilled DMF for 10 minutes.
- Deprotection of Fmoc group was performed with 20% piperidine in DMF for 10 minutes and the deprotection was monitored by UV detection of the column effluent at 304 nm.
- the diester bridge formation was carried out using dicarboxylic acid (1-2 eq.), HBTU (4-6 eq.), HOAt (4-6 eq.), and collidine (6-8 eq.), while lactam bridge was prepared by treating the peptide resin, with solution of HBTU (4-6 eq.), HOBt (4-6 eq.), and DIPEA (8-10 eq.).
- the dried Peptide-resin (ca 10-mg) was treated with mixture (1 mL) of TFA, water, triisopropylsilane (95: 2.5: 2.5 v/v), for 90 minutes at room temperature with gentle occasional swirling.
- the resin was filtered, washed thoroughly with neat TFA (1 mL) and the entire filtrate was evaporated under reduced pressure. Residual TFA was azeotroped three times with diethyl ether (2 mL). Residue obtained was suspended in distilled water (2 mL) and the aqueous layer was extracted three times with diethyl ether (3 mL). The aqueous layer was separated and freeze-dried to yield the crude
- the lyophilised peptide Aib-V-Aib-EIK-(aMe-2F-Phe)-Nle-HE-Har-A-Cit-(otMe-2F-Phe) was dissolved in 0.1% aqueous TFA (ca lmg /l mL) and its purity was analyzed by analytical RP-HPLC and characterized by electrospray ionisation mass spectrometry (ESI-MS). Percent purity: 90 % (crude peptide). ESI-MS; Calcd.
- cyclic short-chain peptides designed in the present invention were prepared, using Fmoc-SPPS approach. Furthermore, resin bound cyclic short-chain peptides were cleaved and deprotected, purified and characterized using following protocol.
- the desired cyclic short-chain peptides were cleaved and deprotected from their respective peptidyl-resins by treatment with TFA cleavage mixture as follows.
- a solution of TFA / Water / Triisopropylsilane (95: 2.5: 2.5) (10 mL / 100 mg of peptidyl- resin) was added to peptidyl-resins and the mixture was kept at room temperature with occasional starring.
- the resin was filtered, washed with a cleavage mixture and the combined filtrate was evaporated to dryness.
- a solution of crude peptide dissolved in DMF or water was injected into a semi-Prep column (Luna 10 ⁇ ; Ci 8 ; 100 A 0 ), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 mL / min, with effluent monitoring by PDA detector at 220 nm.
- a typical gradient of 20 % to 70 % of water-ACN mixture, buffered with 0.1 % TFA was used, over a period of 50 minutes, with 1% gradient change per minute.
- each peptide was analyzed by analytical RP-HPLC on a Shimadzu LC-10AD analytical HPLC system.
- analytical HPLC analysis of cyclic short-chain peptides Luna 5 ⁇ ; Ci 8 ; 100 A ° , dimension 250 X 4.6 mm column was used, with a linear gradient of 0.1% TFA and ACN buffer and the acquisition of chromatogram was carried out at 220 nm, using a PDA detector. .
- Each peptide was characterized by electrospray ionisation mass spectrometry (ESI-MS), either in flow injection or LC/MS mode.
- ESI-MS electrospray ionisation mass spectrometry
- Triple quadrupole mass spectrometers API-3000 (MDS-SCIES, Canada) was used in all analyses in positive and negative ion electrospray mode. Full scan data was acquired over the mass range of quadrupole, operated at unit resolution. In all cases, the experimentally measured molecular weight was within 0.5 Daltons of the calculated monoisotopic molecular weight. Quantification of the mass chromatogram was done using Analyst 1.4.1 software.
- novel cyclic short chain peptides were prepared. This list is indicative of the various groups of cyclic short chain peptides, which can be prepared according to the present invention, and are expected to at least include obvious variations of these cyclic short chain peptides. However, such disclosure should not be construed as limiting the scope of the invention in any way.
- Table 2 (i-xvi) novel cyclic short chain peptides of present invention are listed along with their corresponding Seq. ID. No.
- Table 2 (vi): List of cyclic short chain peptides prepared including mass & % purity for several of the peptides prepared.
- liver microsomes (ex-vivo).
- the PTHR is a GPCR and the PTHR agonist binds to it and through signal transduction causes activation of adenylate cyclase and raises intracellular cAMP levels.
- UMR-106 rat osteosarcoma cells Source ATCC
- UMR-106 cells were cultured in DMEM nutrition media (Sigma) containing
- FBS Fetal Bovine Serum
- IX Penstrep 10% Fetal Bovine Serum (FBS) and IX Penstrep.
- Cultured cells were plated at a density of 5 x 10 4 cells per well in DMEM media supplemented with 10% FBS, in 96- well tissue culture plates and grown for 2 days before the efficacy assays. On the day of assay, the growth medium was carefully removed by suction and cells were washed once with 200 ⁇ of PBS, incubated in 90 ⁇ reaction media (plain DMEM media, low
- Seq. ID. 258 73(9) 100 (1) 100 (1) 100 (0.5) a: % degradation of peptides in 24h when incubated with human plasma and values in bracket represent half-life (1 ⁇ 2), in h;
- b % degradation of peptides in 24h when incubated with simulated gastric fluid and values in bracket represent half-life (tin), in h;
- c % degradation of peptides in 24h when incubated with simulated intestinal fluid and values in bracket represent half-life (ti /2 ), in h;
- the ovariectomiced (OVX) rats were used to study anti-osteoporosis activity of test compounds (cyclic short-chain peptides) in vivo.
- the OVX rats develop osteopenia due to ovarian hormone deficiency. Osteopenia can be detected as early as 14 days post OVX, increase for the next 100 days and then stabilised (Wronski T. J., et al., Calcif. Tissue Int., 43(3), 1988, 179-183).
- Lumbar vertebra (L5) was excised, carefully cleaned and collected in formal saline. Femur, tibia and Lumbar vertebra-5 (L5) were later processed for histomorphometric evaluation (Zhang L., et al., Tohoku J Exp Med., 1998, 186(2), 131-41; Tanizawa T., et al., Toxicol Lett., 1998,102, 399-403). Increase in serum Calcium and decrease in Phosphate levels (% change vs PTH) of selected peptides are listed in Table 5.
- the present invention provides a method of making cyclic short chain peptides that function as an agonist of the PTH-1 receptor having different degree of affinity (1-1000 nM concentration) in UMR-106 cells.
- the PTH-1 receptor agonistic activity was assessed by estimation of amount of cAMP released by the test compounds (in vitro).
- OVX mice/ rat models in vivo
- some of the cyclic short-chain peptides showed improvement in bone growth parameters thus making them ideal therapeutic candidates for the treatment and prevention of osteoporosis.
- Novel cyclic short chain peptides of present invention showed increased stability against various proteolytic enzymes and due to increased stability and short chain length, such cyclic short chain peptides can also be delivered by oral route of administration, along with other invensive and non-invensive routes of administration.
- the cyclic short chain peptides of the present invention can be used either alone or in combination with other anti-osteophoratic agents such as growth harmone secretagogues, Insulin-like growth factor (IGF-1), Vitamine-D analogues, estrogen, raloxifene (oestrogen receptor modulators), calcitonin, PTH-1 r agonist and the bisphosphonates (etidronate, alendronate and risedronate) for the treatment and prevention of osteoporosis.
- IGF-1 Insulin-like growth factor
- Vitamine-D analogues Vitamine-D analogues
- estrogen raloxifene (oestrogen receptor modulators)
- calcitonin calcitonin
- PTH-1 r agonist bisphosphonates
- novel cyclic short chain peptides of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients as are well known.
- the pharmaceutical composition containg the short is provided by employing conventional techniques.
- the composition is in unit dosage form containing an effective amount of the active component, that is, the cyclic short-chain peptides of formula (I) either alone or combination, according to this invention.
- the pharmaceutical composition can be prepared by known processes by combining the compound of formula (I) with suitable excipients comprising suitable excipients selected from suitable diluents, stabilizers, buffers and the like as is known in the art.
- the quantity of active component that is, the cyclic short chain peptides of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular short chain peptides and the desired concentration. Generally, the quantity of active component will range between 0.5 % to 90 % by weight of the composition.
- the cyclic short chain peptides of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating or preventing osteoporosis, such as primary osteoporosis, endocrine osteoporosis (hyperthyroidism, hyperparathyroidism, Cushing's syndrome, acromegaly, type 1 diabetes mellitus, adrenal insufficiency), hereditary and congenital forms of osteoporosis (osteogenesis imperfecta, homocystinuria, Menkes' syndrome and Riley-Day syndrome), nutritional and gastrointestinal disorders, haematological disorders/malignancy (multiple myeloma, lymphoma and leukaemia, hemophilia-, thalassemia), osteoporosis due to immobilization, chronic obstructive pulmonary disease or rheumatologic disorders (rheumatoid arthritis, spondylitis), Osteomyelitis
- Hypercalcemia resulting from solid tumours and hematologic malignancies idiopathic hypercalcemia and hypercalcemia associated with hyperthyroidism and renal function disorders.
- Osteopenia following surgery induced by steroid administration and associated with disorders of the small and large intestine and with chronic hepatic and renal diseases.
- Osteonecrosis or bone cell death associated with traumatic injury or nontraumatic necrosis associated with Gaucher's disease, sickle cell anaemia, systemic lupus erythematosus and other conditions.
- Periodontal bone loss, Osteolytic metastasis, bone fracture healing and hyperproliferative skin disorders such as psoriasis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne de nouveaux peptides cycliques à chaîne courte présentant des propriétés pharmaceutiques bénéfiques. L'invention concerne aussi un procédé de préparation de tels peptides à chaîne courte et des compositions phamaceutiques renfermant les peptides cycliques de la présente invention. A-Z 1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-Z 12-Z13-Z 14-Z 15-B (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN301/MUM/2011 | 2011-02-02 | ||
IN301MU2011 | 2011-02-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012120532A2 true WO2012120532A2 (fr) | 2012-09-13 |
WO2012120532A3 WO2012120532A3 (fr) | 2013-03-14 |
Family
ID=46579272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2012/000078 WO2012120532A2 (fr) | 2011-02-02 | 2012-02-02 | Peptides cycliques à chaîne courte |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012120532A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113736741A (zh) * | 2021-08-18 | 2021-12-03 | 上海市食品药品检验研究院 | 一种用于测定特立帕肽生物学活性的克隆化细胞株 |
CN115925802A (zh) * | 2023-02-22 | 2023-04-07 | 西南交通大学 | 一种具有增强抗菌活性和血清稳定性的抗菌肽及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003009804A2 (fr) | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Analogues d'hormone parathyroide (pth) a contrainte conformationnelle |
WO2004067021A1 (fr) | 2003-01-24 | 2004-08-12 | Gardella Thomas J | Analogues de parathormone (pth) a contrainte conformationnelle avec ponts lactame |
WO2004093902A1 (fr) | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | Hormones parathyroidiennes contraintes de maniere conformationnelle avec des stabilisateurs en helice $g(a) |
WO2005077918A1 (fr) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Agonistes de pth |
US20060019902A1 (en) | 2004-07-19 | 2006-01-26 | Andrea Caporale | PTH-like peptides |
US7153951B2 (en) | 1998-10-22 | 2006-12-26 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US20070099940A1 (en) | 2004-02-11 | 2007-05-03 | Spearing Paul K | Pth agonists |
US20070117157A1 (en) | 2002-09-13 | 2007-05-24 | Zajac Jeffrey D | Parathyroid hormone-like polypeptides |
US20070203071A1 (en) | 2003-07-17 | 2007-08-30 | Gardella Thomas J | Conformationally Constrained Parthyroid Hormone (Pth) Analogs |
WO2007130113A2 (fr) | 2005-09-06 | 2007-11-15 | Zelos Therapeutics, Inc. | Analogues de l'hormone parathyroidienne et procedes les utilisant |
WO2008068487A1 (fr) | 2006-12-08 | 2008-06-12 | Zealand Pharma A/S | Peptides pth tronqués à configuration cyclique |
WO2010128521A2 (fr) | 2009-04-24 | 2010-11-11 | Cadila Healthcare Limited | Peptides à chaîne courte comme agoniste du récepteur de l'hormone parathyroïdienne (pth) |
-
2012
- 2012-02-02 WO PCT/IN2012/000078 patent/WO2012120532A2/fr active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153951B2 (en) | 1998-10-22 | 2006-12-26 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US20070111946A1 (en) | 1998-10-22 | 2007-05-17 | Gardella Thomas J | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
WO2003009804A2 (fr) | 2001-07-23 | 2003-02-06 | The General Hospital Corporation | Analogues d'hormone parathyroide (pth) a contrainte conformationnelle |
US20070117157A1 (en) | 2002-09-13 | 2007-05-24 | Zajac Jeffrey D | Parathyroid hormone-like polypeptides |
WO2004067021A1 (fr) | 2003-01-24 | 2004-08-12 | Gardella Thomas J | Analogues de parathormone (pth) a contrainte conformationnelle avec ponts lactame |
WO2004093902A1 (fr) | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | Hormones parathyroidiennes contraintes de maniere conformationnelle avec des stabilisateurs en helice $g(a) |
US20070161569A1 (en) | 2003-03-19 | 2007-07-12 | Gardella Thomas J | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
US20070203071A1 (en) | 2003-07-17 | 2007-08-30 | Gardella Thomas J | Conformationally Constrained Parthyroid Hormone (Pth) Analogs |
WO2005077918A1 (fr) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Agonistes de pth |
US20070099940A1 (en) | 2004-02-11 | 2007-05-03 | Spearing Paul K | Pth agonists |
US20060019902A1 (en) | 2004-07-19 | 2006-01-26 | Andrea Caporale | PTH-like peptides |
WO2007130113A2 (fr) | 2005-09-06 | 2007-11-15 | Zelos Therapeutics, Inc. | Analogues de l'hormone parathyroidienne et procedes les utilisant |
WO2008068487A1 (fr) | 2006-12-08 | 2008-06-12 | Zealand Pharma A/S | Peptides pth tronqués à configuration cyclique |
WO2010128521A2 (fr) | 2009-04-24 | 2010-11-11 | Cadila Healthcare Limited | Peptides à chaîne courte comme agoniste du récepteur de l'hormone parathyroïdienne (pth) |
Non-Patent Citations (64)
Title |
---|
ANDREA C. ET AL., J.M.C., vol. 53, 2010, pages 8072 - 8079 |
ANDREA C. ET AL., JMC., vol. 53, 2010, pages 8072 - 79 |
AZURANI A. ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 14931 - 14936 |
BETSBRUGGE J.V. ET AL., TETRAHEDRON, vol. 54, 1988, pages 1753 - 1762 |
BOESTEN, W.H.J. ET AL., ORG. LETT., vol. 3, no. 8, 2001, pages 1121 - 1124 |
CARTER P. H. ET AL., PNAS, vol. 104, no. 16, 2007, pages 6846 - 6851 |
CATIVIELA C.; DIAZ-DE-VILLEGAS M. D., TETRAHEDRAN ASYMMETRY, vol. 9, 1988, pages 3517 - 3599 |
CHOREV M., ACC. CHEM. RES., vol. 26, 1993, pages 266 - 273 |
COLE Z. A. ET AL., CURR. RHEUMATOL. REP., vol. 10, no. 2, 2008, pages 92 - 96 |
DEMPSTER D. W. ET AL., ENDOCR. REV., vol. 14, 1993, pages 690 - 709 |
DONNELLY D., FEBS LETTS., vol. 409, 1997, pages 431 - 436 |
E. ATHERTON; R.C. SHEPPARD: "Special methods in peptide synthesis, Part C", vol. 9, 1987, ACADEMIC PRESS, article "The Fluorenylmethoxycarbonyl amino protecting group'', in ''The peptides: Analysis, synthesis, Biology", pages: 1 - 38 |
E. GROSS; J. MEINHOFER: "The peptide synthesis, analysis, biology", vol. 1, 1979, ACADEMIC PRESS |
G. BARANY; R. B. MERRIFIELD: "Special methods in peptide synthesis, Part A", vol. 2, 1980, ACADEMIC PRESS, article "The peptides: Analysis, synthesis, Biology", pages: 3 - 284 |
GARDELLA T. J. ET AL., ENDOCRINOLOGY, vol. 132, 1993, pages 2024 - 2030 |
GARDELLA T. J. ET AL., ENDOCRINOLOGY, vol. 142, 2001, pages 3068 - 3074 |
GARDELLA T. J. ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 13141 - 13146 |
GARDELLA T. J. ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 21836 - 21843 |
GARDELLA T. J. ET AL., J. BIOL. CHEM., vol. 52, 2001, pages 49003 - 49012 |
GOLTZMAN D., J. BONE MINER. RES., vol. 15, no. 3, 2000, pages 605 - 608 |
GREENSPAN S. L. ET AL., ANN. INTERN. MED., vol. 146, no. 5, 2007, pages 326 - 339 |
HARVEY, N. ET AL., CURR. RHEUMATOL. REP., vol. 5, no. 1, 2003, pages 75 - 81 |
HJORTH, S. A. ET AL., REGULATORY PEPTIDES, vol. 64, 1996, pages 70 |
HOARE S. R. J. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 7741 - 7753 |
HOARE, S. R. J., DRUG DISCOVERY TODAY, vol. 10, 2005, pages 423 - 427 |
J. M. STEWART; J. D. YOUNG: "Solid-phase peptide synthesis,2nd Ed.,", 1984, PIERCE CHEMICAL CO. |
J. MED. CHEM., vol. 53, 2010, pages 8072 - 8079 |
JI T. H ET AL., J. BIOL. CHEM., vol. 273, 1988, pages 17299 - 17302 |
JUPPNER H. ET AL., SCIENCE, vol. 254, 1991, pages 1024 - 1026 |
KING D.S. ET AL., INT. J. PEPTIDE PROTEIN RES., vol. 36, 1990, pages 255 - 266 |
KOLAKOWSKI L. F., RECEPTOR CHANNELS, vol. 2, 1994, pages 1 - 7 |
KRONENBERG H. M.; BRINGHURST F. R.; NUSSBAUM S. R.; JUPPNER H.; ABOU-SAMRA A. B.: "Handbook of Experimental Pharmacology", 1993, SPRINGER-VERLAG, pages: 185 - 201 |
KUIJPERS G., BMJ, vol. 324, no. 7335, 2002, pages 435 - 436 |
LANE J. M. ET AL., CLIN. ORTHOP. RELAT. RES, vol. 372, 2000, pages 139 - 150 |
LANSKE B. ET AL., CRIT. REV. EUKARYOT. GENE EXPR., vol. 8, 1998, pages 297 - 320 |
LINDSAY R., LANCET, vol. 341, no. 8848, 1993, pages 801 - 805 |
LUCK M. D. ET AL., MOLECULAR ENDOCRINOLOGY, vol. 13, 1999, pages 670 - 680 |
M. BODANSKY; A. BODANSKY: "The practice of peptide synthesis", 1984, SPRINGER-VERLAG |
MERRITT B. S., J. CELLULAR PHYSIOLOGY, vol. 152, no. 3, 2005, pages 520 - 528 |
NAUSSBAUM S. R. ET AL., J. BIOL. CHEM., vol. 255, 1980, pages 10183 - 10187 |
NEER R. M. ET AL., N. ENGL. J. MED, vol. 344, 2001, pages 1434 - 1441 |
NEER R. M. ET AL., N. ENGL. J. MED., vol. 344, 2001, pages 1434 - 1441 |
OLSON G. L. ET AL., J. MED. CHEM., vol. 36, no. 21, 1993, pages 3039 - 3049 |
RECKER R. R., J. CLIN. ENDOCRINOL. METAB., vol. 76, no. 1, 1993, pages 14 - 16 |
REID I. R., AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 253, 1987, pages E45 - E50 |
REIDHAAR-OLSON J. F. ET AL., MOL. CELL. ENDOCRINOLOGY., vol. 160, 2000, pages 135 - 147 |
RIXON R. H. ET AL., J. BONE MINER. RES., vol. 9, 1994, pages 1179 - 1189 |
SEEMAN E. ET AL., N. ENGL. J. MED., vol. 354, no. 21, 2006, pages 2250 - 2261 |
SHIMIZU M. ET AL., ENDOCRINOLOGY, vol. 142, 2001, pages 3068 - 3074 |
SHIMIZU M. ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 21836 - 21843 |
SHIMIZU N. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 49003 - 49012 |
SLOVIK D. M. ET AL., J. BONE MINER. RES., vol. 1, 1986, pages 377 - 381 |
TAKASU H ET AL., BIOCHEMISTRY, vol. 38, 1999, pages 13453 - 13460 |
TANIZAWA T. ET AL., TOXICOL LETT., vol. 102, 1998, pages 399 - 403 |
TREGEAR G. W. ET AL., ENDOCRINOLOGY, vol. 93, 1973, pages 1349 - 1353 |
VAHLE J. L., TOXICOL. PATHOS., vol. 32, no. 4, 2004, pages 426 - 438 |
WHITEFILD J. F. ET AL., CALCIF. TISSUE INT., vol. 56, 1995, pages 227 - 231 |
WHITFIEL J. F., MEDSCAPE WOMENS HEALTH, vol. 6, no. 5, 2001, pages 7 |
WHITFIELD J. F. ET AL., CALCIF. TISSUE INT., vol. 58, 1996, pages 81 - 87 |
WHITFIELD J. F. ET AL., J. BONE MINER. RES., vol. 12, 1997, pages 1246 - 1252 |
WHITFIELD J. F. ET AL., TRENDS PHARMACOL. SCI., vol. 16, 1995, pages 372 - 386 |
WRONSKI T. J. ET AL., CALCIF. TISSUE INT., vol. 43, no. 3, 1988, pages 179 - 183 |
ZHANG L. ET AL., TOHOKU J EXP MED., vol. 186, no. 2, 1998, pages 131 - 41 |
ZUBAY, G.: "Biochemistry 2nd ed.,", 1988, MACMILLAN PUBLISHING, pages: 33 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113736741A (zh) * | 2021-08-18 | 2021-12-03 | 上海市食品药品检验研究院 | 一种用于测定特立帕肽生物学活性的克隆化细胞株 |
CN115925802A (zh) * | 2023-02-22 | 2023-04-07 | 西南交通大学 | 一种具有增强抗菌活性和血清稳定性的抗菌肽及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2012120532A3 (fr) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2757874C (fr) | Peptides a chaine courte comme agoniste du recepteur de l'hormone parathyroidienne (pth) | |
KR0173478B1 (ko) | 부갑상선 호르몬 길항물질 | |
JP4541899B2 (ja) | ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン(pth)アナログ | |
SK155694A3 (en) | Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters | |
NZ312899A (en) | Peptidyl analogs of a fragment (1-34) of parathyroid hormone | |
EP1439854B1 (fr) | Analogues d'hormone parathyroide (pth) a contrainte conformationnelle | |
NZ336610A (en) | Analogs of parathyroid hormone | |
JP4334480B2 (ja) | α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン | |
KR20220035199A (ko) | 인크레틴 유사체의 제조 방법 | |
US20210107953A1 (en) | Active polypeptide compound | |
Greenberg et al. | Mitogenic action of osteogenic growth peptide (OGP) Role of amino and carboxy-terminal regions and charge | |
Dong et al. | Engineering of therapeutic polypeptides through chemical synthesis: early lessons from human parathyroid hormone and analogues | |
HUT69708A (en) | Process for producing parathormon fragments and pharmaceutical compositions containing them | |
KR20010085847A (ko) | 펩티드 유도체 | |
KR101417872B1 (ko) | 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(igf-1)의 유사체 | |
EP0773958A1 (fr) | ANTAGONISTES DE LA PTH OU DU PTH-rP | |
Raisz et al. | Comparison of the effects of a potent synthetic analog of bovine parathyroid hormone with native bPTH-(1-84) and synthetic bPTH-(1-34) on bone resorption and collagen synthesis | |
WO2012120532A2 (fr) | Peptides cycliques à chaîne courte | |
KR101108354B1 (ko) | Pth 수용체 조절제로서의 페길화된 pth 및 그의 용도 | |
JPH07316195A (ja) | 新規なPTHrP関連ペプチド及びその用途 | |
Klasová et al. | Effect of N-methylation of the peptide bond in the C-terminal part of the B-chain of human insulin on biological activity | |
WO1996029343A1 (fr) | Nouveaux derives de calcitonine | |
JPH04217997A (ja) | ペプチド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12738621 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12738621 Country of ref document: EP Kind code of ref document: A2 |